SNT

SYNTARA FPO [SNT]
Syntara Limited, a clinical-stage drug development company, that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate is amsulostat, which has completed Phase 2a clinical trial for the treatment of bone marrow cancer myelofibrosis, as well as in Phase 1c/2 clinical trial for patients with myelodysplastic syndrome and in Phase 1/2 clinical trial to treat pancreatic cancer. The company also develops topical pan-LOX inhibitors with SNT-9465, which is in a Phase 1a/b study for hypertrophic scars; SNT-6302 for the treatment of keloid scars; and SNT-4728 to treat sleep behaviour disorders and slow progression of neurodegenerative diseases by reducing neuroinflammation. In addition, it develops other drug candidates to treat fibrotic and inflammatory diseases, including kidney fibrosis, MASH, pulmonary fibrosis, and cardiac fibrosis. The company has a collaboration agreement with the University of Western Australia to studying SNT-6302 in keloid scars. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.
Healthcare · ASX Small Cap
$0.0240 -4.0%

Updated 9 Sep 2026 · Signals refresh every scan

Appeared in 3 consecutive scansFirst seen: 2026-02-25
Get alerts when SNT triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track SNT — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • MACD momentum is losing steam
  • Sitting right at the lower Bollinger Band — oversold and potentially ready to snap back
  • Bollinger Bands are tightening — volatility is coiling up for a potential breakout
  • Sitting near support — this level has held before and could attract buyers again
  • Drifting lower — down 7.7% over the last 5 days
  • Volatility is contracting — like a spring being compressed, breakouts often follow
  • Adequate cash runway (6 quarters)
  • Moderate P/S ratio (6.8x)
  • EPS estimates revised upward (+10pts)
  • Small-cap ($20-100M)
  • CANSLIM I: Institutional ownership (15%)
  • Sentiment is mixed — no strong consensus either way
  • Altman Z-Score distress zone (1.61 < 1.81, low-confidence approx)
  • Low-priced stock risk ($0.024)
  • RBA hiking (-3pts)

Risk Signals

  • Below the 200-day average — the long-term trend is still working against it
  • Revenue declining (-13%)
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Deeply negative margins (-130%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Revenue declining at -13% — the top line is shrinking
  • The bigger volume days are the down days — volume-weighted momentum is negative (-1.85%/day)

Expected next for SNT

4 Nov 2026Quarterly Cash Flow Report (4C)Estimated from past filings
Window: 28 Oct to 11 Nov
The last 6 moved SNT -0.8% on the day, on average — an observation, not a guide to what happens next.
Each date is labelled with how it is known. A date estimated from past filings is inferred from this company's own filing rhythm — it is not a confirmed date and not a statement about what the company intends to do. See the whole ASX calendar →

Recent Catalysts

NONE Appendix 4G and Corporate Governance Statement
NONE Investor Update Webinar Presentation
NONE Investor Update Webinar
LOW Appendix 4E and Annual Report
LOW Investor Presentation

Recent ASX Announcements

2026-08-27 Appendix 4G and Corporate Governance Statement
2026-08-27 Appendix 4E and Annual Report PRICE SENSITIVE
2026-07-28 Investor Update Webinar Presentation
2026-07-26 Investor Update Webinar
2026-07-26 Investor Presentation

Key Metrics

$47.1M
Market Cap
818K
Avg Volume
1.3x
Vol Ratio
$0.02 — $0.04
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-59.7%
ROE
-129.8%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 78%
LLeader vs LaggardlaggardRS: 0
IInstitutional SponsorshippassInst: 15%
MMarket DirectionneutralNeutral

Sector: Healthcare

110 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
NUZ +37.1%IPD +20.0%HIQ +16.7%AVE +15.0%CVB +11.1%
Compare:SNT vs NUZSNT vs IPDSNT vs HIQ
Share this analysis

Track SNT and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required